Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology
Giulia Albertini, Magdalena Zielonka, Marie‐Lynn Cuypers, Veerle van Lieshout, An Snellinx, Emanuela Pasciuto, Leen Wolfs, Katleen Craessaerts, Katrien Horré, Tom Jaspers, Mark Fiers, Maarten Dewilde, Bart De Strooper · 2025
Read Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology by Giulia Albertini, Magdalena Zielonka, Marie‐Lynn Cuypers, Veerle van Lieshout, An Snellinx, Emanuela Pasciuto, Leen Wolfs, Katleen Craessaerts, Katrien Horré, Tom Jaspers, Mark Fiers, Maarten Dewilde, Bart De Strooper (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11710208.txt.
Description
Giulia Albertini and co-authors report a 2025 conference abstract on how the Alzheimer's drug lecanemab works. The antibody lowers amyloid, but its inner mechanism has been unclear. The team used mice that grow amyloid pathology yet are born without microglia, the brain's immune cells, to test whether the drug needs those cells.
Without microglia, lecanemab lost its effect. When human microglia were transplanted into the mouse brains, the drug again cut amyloid load and nerve fiber damage. Gene readouts showed the treated human cells switched on eating, interferon, and immune programs. Treated cells also swallowed more amyloid in the living brain.
Catalog record
| CREATOR | Giulia Albertini, Magdalena Zielonka, Marie‐Lynn Cuypers, Veerle van Lieshout, An Snellinx, Emanuela Pasciuto, Leen Wolfs, Katleen Craessaerts, Katrien Horré, Tom Jaspers, Mark Fiers, Maarten Dewilde, Bart De Strooper |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |